For the 10,000+ people
who have been treated with SPINRAZA worldwide,*
victories are personal.

*Based on commercial patients, early access patients, and clinical trial participants through December 2019.

Discover SPINRAZA: the first FDA-
approved treatment for SMA

6+ years

Safety and efficacy
evaluated
in the longest
clinical trial in
SMA to date

3x/year

SPINRAZA is delivered directly to

the central nervous system (CNS)
where
motor neuron loss begins.
After
initial loading doses,
SPINRAZA is
given 3 times a year.

an adult with later-onset SMA who is being treated with SPINRAZA
an adult with later-onset SMA who is being treated with SPINRAZA

From 3 days to 80 years old‡§

There’s someone from almost every age group who has been treated with SPINRAZA.

Includes clinical trial patients.

Clinical studies of SPINRAZA did not include sufficient numbers of subjects aged 65 and older to determine
whether they respond differently from younger patients.

§Based on commercial patients in the US (including Puerto
Rico) through December 2019.

Demonstrated efficacy in people with early and later-onset SMA

a child with later-onset SMA who is being treated with SPINRAZA
a child with later-onset SMA who is being treated with SPINRAZA

Safety & side effects

The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA.

How SPINRAZA works

SPINRAZA targets an underlying cause of muscle weakness in SMA.